Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Top Cited Papers
Open Access
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 153 (4), 996-1005.e1
- https://doi.org/10.1053/j.gastro.2017.06.012
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related CirrhosisGastroenterology, 2017
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsGastroenterology, 2017
- Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated CirrhosisClinical Gastroenterology and Hepatology, 2016
- Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisClinical Gastroenterology and Hepatology, 2016
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJournal of Hepatology, 2016
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyJournal of Hepatology, 2016
- Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antiviralsJournal of Hepatology, 2016
- Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancerCancer, 2016
- Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infectionJournal of Hepatology, 2016
- Hepatocellular CarcinomaThe New England Journal of Medicine, 2011